Earnings call transcript: Pulmonx Q3 2026 beats forecasts, shares jump 13%

Pulmonx reported Q3 2026 revenue of $22.8 million, up 6% year over year and 3.97% above forecasts, while its $0.19-per-share loss was narrower than the expected $0.26. Net loss declined 40% to $8.4 million and adjusted EBITDA loss fell nearly 60% to $3.5 million; the company reiterated 2026 revenue guidance of $90 million-$92 million. Shares rose 12.73% after hours to $2.23. Growth has returned, but Pulmonx remains unprofitable and management did not provide 2027 guidance.

Analysis

The investable signal is whether account-level procedure volumes—not simply new center openings—can sustain growth as the rebuilt sales force matures. With most U.S. territories now staffed but median tenure still short, near-term growth has execution risk: productivity may improve with ramp, yet uneven rep performance could make quarterly results volatile. Track procedures or utilization per treating center, where disclosed, alongside U.S. growth; center additions alone are a weak leading indicator.

The cost reset creates leverage only if revenue compounds. Management’s expectation of largely flat operating costs makes incremental sales valuable, but the quarter does not yet establish a durable growth rate or cash-flow breakeven. The stated cash-burn outlook provides a buffer, while access to additional credit is conditional on revenue milestones; verify facility terms, debt outstanding, and milestone status before treating liquidity as a floor. China is a modest, potentially lumpy contributor rather than a core thesis. AeriSeal is even further out: trial progress and regulatory/commercial execution matter more than its claimed market expansion today.

Near term, the after-hours repricing risks pulling forward much of the good news. Over the next 1–3 months, Q4 delivery against guidance and evidence of broad-based U.S. account productivity are the key catalysts. Over 6–18 months, sustained growth and trial progress could improve the financing narrative; stalled adoption or delayed China/AeriSeal timelines would reverse it. Contrarian point: the headline beat is less important than the possibility that a smaller, focused commercial footprint can grow without renewed expense inflation—but one quarter is insufficient proof.

Key Decisions for Investors

• Do not chase the post-earnings gap. Consider a small, staged long in LUNG only after volatility settles, with the next earnings report as the principal confirmation point; the thesis is improving sales productivity and operating leverage, not China or near-term AeriSeal revenue.
• For the next report, verify revenue against the 2026 range and seek evidence that U.S. growth is translating into higher utilization at existing centers. Treat slowing U.S. growth, weaker gross margin, or operating expenses rising materially faster than revenue as thesis-breakers.
• Model China shipments as upside optionality, not a base-case growth engine: management describes the contribution as small and distributor sales as less predictable. Reassess only when shipment timing and realized revenue are disclosed.
• Keep AeriSeal out of near-term earnings assumptions until trial enrollment, regulatory milestones, and launch timing are independently substantiated; a delay in enrollment completion or European launch would defer the longer-dated expansion case.